• News

A New Treatment Could Deal '1, 2 punch' to Non-Hodgkin's Lymphoma and Other Incurable Cancers

  • Good Morning America
  • New York, NY
  • (April 10, 2019)

Non-Hodgkin’s lymphoma (NHL) is a unique cancer that originates in the white blood cells of the human bone marrow. It is the seventh most common cancer in the United States. Researchers at Mount Sinai in New York have used a form of NHL to develop a novel approach to cancer immunotherapy, injecting immune stimulants directly into a tumor to teach the immune system to destroy it and other tumor cells throughout the body, Dr. Joshua Brody, director of immunotherapy at Mount Sinai, told ABC News. “While most vaccines we think about (like polio vaccine) are preventative, researchers are also developing therapeutic cancer vaccines, which can treat people who have already developed the disease,” Dr. Brody said. The study is still in early clinical phases and has been tested on 11 patients with indolent non-Hodgkin’s B cell lymphoma. Dr. Brody said the patients tolerated the treatments well and early results have been very positive, providing prolonged remission rates in these patients.

— Joshua Brody, MD, Director, Lymphoma Immunotherapy Program, Assistant Professor, Medicine, Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai

Learn More 

Related Articles